おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Overview
- Gender
- female
Helene joined UCB (then Celltech) in 1989 after 2 years at the MRC Laboratory of Molecular Biology Cambridge, and has gained expertise in a range of antibody technologies. Her PhD studies at UCB in gene therapy generated the first co-stimulation signal inclusive (now termed “second generation”) CAR-T cell constructs. She has led a variety of antibody technology teams & early stage therapeutic antibody discovery projects for oncology, bone, immunology/inflammation & CNS targets. Helene now leads the UCB Functional Screening project team; combining cutting edge antibody & screening technology to discover break-through bispecific antibody drugs across multiple therapeutic areas.
Jobs
Number of Current Jobs
2
Helene Finney has 2 current jobs including
Head of Bispecific Target Discovery at UCB
,
Director, Functional Screening at UCB
and
.
| Organization Name | Title At Company | Start Date | End Date | |
|---|---|---|---|---|
UCB
|
Head of Bispecific Target Discovery | Jan 1, 2019 | — | Detail |
|
UCB
|
Director, Functional Screening | Aug 1, 1989 | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
